Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ALBIREO PHARMA, INC.

(ALBO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Albireo to Host KOL Event on Progressive Familial Intrahepatic Cholestasis

10/16/2017 | 08:01am EST

BOSTON, Oct. 16, 2017 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today that it will host a Key Opinion Leader (KOL) breakfast meeting focused on the topic of progressive familial intrahepatic cholestasis (PFIC), a pediatric orphan liver disease, at the Lotte Palace Hotel in New York City on Wednesday, October 25, 2017, from 8:00 a.m. to 9:30 a.m. ET.

The meeting will feature a presentation by Ekkehard Sturm, M.D., Ph.D., pediatric hepatologist and the head of pediatric gastroenterology-hepatology, liver and intestinal transplantation at Children’s Hospital, University of Tuebingen in Germany. Dr. Sturm will address the current therapeutic landscape and unmet medical need in the treatment of children with PFIC and will be available to answer questions following the meeting.

In addition, Albireo management will provide an overview of Albireo’s planned Phase 3 clinical program for A4250 in children with PFIC.

Dr. Sturm serves as the pediatric coordinator of the European Reference Network RARE LIVER. He has authored or co-authored more than 50 original manuscripts, reviews and case reports published in such journals as Journal of Pediatric Surgery, Pediatric Transplantation, European Journal of Pediatrics, The Lancet, Journal of Hepatology and HEPATOLOGY. In addition, he has authored six textbook chapters on topics such as PFIC, disorders of the intrahepatic bile ducts, and living donation for liver transplantation. Dr. Sturm is a member of the American Association for the Study of Liver Diseases, the German Society for Pediatric Gastroenterology and Nutrition, the German Society of Pediatrics and Adolescent Medicine, the Dutch Society for Pediatrics and the European Society for Pediatric Gastroenterology, Hepatology and Nutrition. He holds advanced degrees from Hannover Medical School in Germany and The University Medical Center Groningen in the Netherlands and trained as a post-doctoral research fellow at Yale University.

To register to attend the event, contact LifeSci Advisors, LLC at Mac@LifeSciAdvisors.com.  Advanced registration is required, as space is limited.

A live and archived webcast of the event will be available on the Investors page of Albireo’s website at http://ir.albireopharma.com.  To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. The archived version of the webcast will be available for replay on the Events & Presentations section of the Investors page of Albireo's website for at least two weeks following the event.

About Albireo
Albireo is a clinical-stage biopharmaceutical company focused through its operating subsidiary on the development of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Albireo’s clinical pipeline includes a Phase 3 product candidate, a Phase 2 product candidate and a product candidate for which an application for regulatory approval has been submitted in Japan. Albireo was spun out from AstraZeneca in 2008.

Albireo Pharma is located in Boston, Massachusetts, and its key operating subsidiary, Albireo AB, is located in Gothenburg, Sweden. For more information on Albireo, please visit www.albireopharma.com.

Investor Contact:
Hans Vitzthum
LifeSci Advisors, LLC.
212-915-2568

Media Contact:
Heather Anderson
6 Degrees
980-938-0260
handerson@6degreespr.com

Source: Albireo Pharma, Inc.

Primary Logo


ę GlobeNewswire 2017
All news about ALBIREO PHARMA, INC.
08:31aAlbireo Expands Leadership with Constantine Chinoporos as Chief Business Officer
GL
11/16ALBIREO PHARMA : Post-AASLD Business Update
PU
11/12Albireo Announces New Phase 3 Data for Bylvay™ (odevixibat) in PFIC and First Rev..
AQ
11/12Albireo Announces New Phase 3 Data for Bylvay? in Pfic and First Reveal of New Next Gen..
CI
11/10Albireo to Present at Upcoming Investor Conferences
AQ
11/04Albireo Pharma Swings to Q3 Gain on Sale of Priority Review Voucher; Shares Fall
MT
11/04ALBIREO PHARMA, INC. Management's Discussion and Analysis of Financial Condition and R..
AQ
11/04Albireo Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months End..
CI
11/04Albireo Reports Q3 Financial Results and Business Update - Form 8-K
PU
11/04Earnings Flash (ALBO) ALBIREO PHARMA Posts Q3 Revenue $3.7M
MT
More news
Analyst Recommendations on ALBIREO PHARMA, INC.
More recommendations
Financials (USD)
Sales 2021 13,0 M - -
Net income 2021 -68,2 M - -
Net cash 2021 208 M - -
P/E ratio 2021 -6,68x
Yield 2021 -
Capitalization 454 M 454 M -
EV / Sales 2021 19,0x
EV / Sales 2022 7,06x
Nbr of Employees 90
Free-Float 87,3%
Chart ALBIREO PHARMA, INC.
Duration : Period :
Albireo Pharma, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALBIREO PHARMA, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 23,55 $
Average target price 73,50 $
Spread / Average Target 212%
EPS Revisions
Managers and Directors
Ronald H. W. Cooper President, Chief Executive Officer & Director
Simon John Harford Chief Financial Officer & Treasurer
David John Chiswell Chairman
Jan Peter Mattsson Chief Scientific Officer, Managing Director-Sweden
Patrick Taylor Horn Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
ALBIREO PHARMA, INC.-38.74%443
GILEAD SCIENCES, INC.18.31%86 465
BIONTECH SE310.30%80 784
WUXI APPTEC CO., LTD.26.13%67 780
REGENERON PHARMACEUTICALS31.76%65 932
VERTEX PHARMACEUTICALS-13.26%52 122